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Abstract
Background: Parkinson’s disease (PD) is accompanied by dysfunctions in a variety of cognitive processes. One of these is
error processing, which depends upon phasic decreases of medial prefrontal dopaminergic activity. Until now, there is no
study evaluating these processes in newly diagnosed, untreated patients with PD (‘‘de novo PD’’).
Methodology/Principal Findings: Here we report large changes in performance monitoring processes using event-related
potentials (ERPs) in de novo PD-patients. The results suggest that increases in medial frontal dopaminergic activity after an
error (Ne) are decreased, relative to age-matched controls. In contrast, neurophysiological processes reflecting general
motor response monitoring (Nc) are enhanced in de novo patients.
Conclusions/Significance: It may be hypothesized that the Nc-increase is at costs of dopaminergic activity after an error; on
a functional level errors may not always be detected and correct responses sometimes be misinterpreted as errors. This
pattern differs from studies examining patients with a longer history of PD and may reflect compensatory processes,
frequently occurring in pre-manifest stages of PD. From a clinical point of view the clearly attenuated Ne in the de novo PD
patients may prove a useful additional tool for the early diagnosis of basal ganglia dysfunction in PD.
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Introduction
When subjects commit an error in speeded reaction time tasks, a
large phasic negative wave with fronto-central midline maximum,
called ‘‘error negativity’’ (Ne) [1], or ‘‘error related negativity’’
(ERN) [2], is seen in the electroencephalogram (EEG), which is
likely generated in the anterior cingulate cortex (ACC). A recent
theory assumes that if an event is worse than expected (i.e. an
error), the DA system sends a signal to the anterior cingulate
cortex (ACC), which in turn elicits the Ne [3]. DA influx to the
prefrontal cortex (PFC) may serve as a gating signal that instructs
the network when to maintain a given activity state [4]. Its
neuromodulatory effects may strengthen current representations,
protecting them against interference from disruption by irrelevant
distracting information [4,5]. In accordance with the dependence
of the Ne on the DA-system, the Ne has been shown to be
decreased in basal ganglia disorders like Parkinson’s (PD), or
Huntington’s disease (HD) [6–8]. Regarding PD, another group
[9] found no such reduction in similarly affected PD patients,
which has been attributed to possible medication effects. However,
it has been shown that medication unlikely affects the modulation
of the Ne [10], but the question remains, whether long-term L-
dopa medication causes a Ne reduction. Recently, Stemmer et al.
[11] found no difference between an early stage PD-group and
patients with a long history of medication, also arguing against
medication effects on the Ne. Hence the most straightforward
approach is to measure the Ne in newly diagnosed patients that
are drug-naive, so called ‘‘de novo’’ patients. Analyses in existent
studies was restricted to error-related processes, but not on
processes related to general response monitoring. Here a
component occurring after correct responses (‘‘CRN’’) [12] or
(‘‘Nc’’) [13] is of importance. The Nc has been related to response
monitoring [14] or to conflict between the actual response and a
response program [15]. Allain et al. [16] have shown that the Nc is
reduced in a correct trial preceding an error trial. This supports
the monitoring hypothesis and suggests that the Nc is necessary for
the maintenance of the proper stimulus-response mapping.
Another recent study [13] further suggested that processes
reflected by the Nc are generally evident after reactions (reflecting
motor response monitoring), and that errors are adding specific
processes on these, constituting the Ne [13,17]. The Nc has
occasionally been found to be enhanced in healthy elderly [18],
while the Ne has been reported to be reduced in elderly [19].
Similarly, abnormally large Ncs have been observed in patients
with PFC-lesions [18] and patients with schizophrenia a disorder
known to be associated with PFC dysfunction [20,21]. According
to Coles et al. [22] a damage to prefrontal cortex, or to the
pathway from prefrontal cortex to the basal ganglia, is leading to
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abnormally large Ncs on correct trials. However, the prefrontal
cortexhasbeen foundtobe dysfunctionalinPD[23–25],whichmay
well affect the Nc, hence leading to abnormally large Ncs in PD.
In the light of a decreased dopaminergic function in older
compared to younger as well as in PD-patients compared to
healthy controls [26,27] this may suggest that an error-specific
activity (i.e. Ne) protecting a task relevant representation is
reduced in its function, while a more general activity, which is
evident in correct (Nc) and error trials [13] is enhanced, possibly
reflecting a compensatory mechanism. Such a compensatory
pattern may be particularly present in newly diagnosed PD
patients [28].
In summary the study specifically examines differences in tonic
and phasic post-response monitoring processes between de novo
PD-patients and healthy controls. Our objective was to test the
following hypotheses: first, based on the assumption that the
amplitude of the Ne depends on the DA system, we expect that the
amplitude of the Ne will be reduced in drug-naive PD patients.
Second, the Nc amplitude should be enhanced in de novo PD-
patients reflecting the increased overall response monitoring [29]
or reflecting the impairment of the correct response representation
[22], because prefrontal cortex dysfunctions, frequently observed
in PD [23–25].
Materials and Methods
Subjects
Fourteen newly diagnosed drug-naı ¨ve patients with idiopathic
PD (7 women) were recruited via the PD out patient unit of the
Neurological Clinic, St. Josefs-Hospital, Ruhr-University of
Bochum (RUB) and of the Neurological Clinic, Klinikum
Dortmund. The mean age of the patients was 59.6 years.
Parkinson’s disease was diagnosed by means of clinical assessment
by the co-authors T.M. and M.S. Subsequently to initial clinical
diagnosis all patients were immediately enrolled in the study
(between 1 and 3 days after clinical diagnosis). Treatment was
postponed until the study protocol (ERP-examination) was
completed. To each patient a healthy control subject (N=14)
was matched by age, sex, and educational background. The mean
age of the controls was also 59.6 years. None of the control
subjects had any history of other neurological or psychiatric
disorders, or was taking any drugs affecting the central nervous
system. All participants gave signed informed consent after they
were informed about the purpose of the study and the protocol
was explained to them. The entire study was approved by the
ethics committee of the University of Mu ¨nster. The socio-
demographic data of the Ss are given in Tab. 1. All subjects were
tested with a battery of standard intelligence and neuropsycho-
logical tests in a separate session before the main EEG session. The
Multiple Choice Intelligence Test (MWT-B) [30] is a test for
crystallized intelligence routinely used in Germany. As a
neuropsychological test of executive functioning the Wisconsin
Card Sorting Test (WCST) [31] was used. In order to control for
depression, the German version of the Beck Depression Inventory
(BDI) was carried out [32]. The clinical testing was conducted with
the Unified Parkinson’s Disease Rating Scale (UPDRS) [33]. The
neuropsychological data is given in Table 1, too. In the
neuropsychological tests there was no significant difference
between the patients and the controls. The overall depression
score was relatively low and well below the threshold for
depression. However it was higher in the patients (8.3) than in
the controls (2.5) (t=4.3, p,.0001).
All participants including PD-patients were free of any
medication.
Modified flanker task
The task was originally designed by Kopp et al. [34] and slightly
modified for our study. The stimuli consisted of vertical arrays of
arrowheads or circles (see Figure S1). The central part of the
stimulus was defined as target. When the target was an arrowhead
the subjects had to press a button on the side the target pointed to;
when the target was a circle, no response had to be given (Nogo
trials). Above and below each target a flanker was presented which
pointed either to the same side (congruent trials) or to the opposite
side (incongruent trials) of the target. Nogo and incongruent trials
had a probability of 20% each, congruent trials had a probability
of 60%. By making the incongruent stimuli relatively rare we
aimed at increasing interference and hence the error rate in the
incongruent condition [35]. Right and left pointing flankers were
equiprobable. The flankers preceded the targets by 100 ms
(Stimulus Onset Asynchrony, SOA=100 ms) to further strengthen
their influence and consequently further increase the error rate in
incongruent trials [36]. Flankers and targets were switched off
100 ms after target onset. The next flanker was presented 800 to
1200 ms (interval randomized) after the response of the subjects,
or 1900 to 2300 ms after a Nogo target. Altogether 420 stimuli
were presented in four blocks of 105 stimuli each, which were
interrupted by short breaks. The subjects were asked to react as
fast as possible to the arrowhead targets.
Table 1. Demographic and clinical characteristics of de novo PD and control subjects.
de novo PD n=14 Controls n=14
Mean (SD) Range Mean (SD) Range
Age 58.9 (10.4) 41–75 59 (11.0) 40–74
MWT-B 112 (11.4) 92–130 127 (13.8) 104–130
UPDRS (motor score) 12.5 (5.6) 3–21 N/A N/A
BDI 8.2 (4.7) 1–17 2.6 (2.4) 0–10
WCST (errors) 34.2 (24.5) 8–84 23.7 (17.3) 8–63
WCST (perseverative errors) 18.2 (19.1) 4–73 11.8 (9.1) 4–33
WCST (categories completed) 4.3 (2.4) 0–6 5.4 (1.5) 1–6
N/A, does not apply. MWT-B, Multiple Choice Intelligence Test; UPDRS, Unified Parkinson’s Disease Rating Scale; BDI, Beck Depression Inventory; WCST, Wisconsin Card
Sorting Test.
doi:10.1371/journal.pone.0004898.t001
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Pressure-sensitive buttons were mounted at the top of the bars and
had to be operated with the right and left thumb. Time pressure
was administered by an individual deadline and was determined
using the error rates in the training session as indicator. A feedback
tone (1000 Hz) was presented 500 ms after the response, if the RT
was slower than the deadline RT.
EEG recording and analysis
During task performance the electroencephalogram (EEG) was
recorded from 26 electrodes: Fp1, Fpz, Fp2; F7, F3, Fz, F4, F8;
FC5, FC3, FCz, FC4, FC6; C3, Cz, C4; P7, P3, Pz, P4, P8; M1,
M2; O1, Oz, O2. The vertical EOG was recorded from 4
electrodes above and below both eyes, and the horizontal EOG
from 2 electrodes at the outer canthi of the eyes. The amplifier
EPA-5 (Sensorium Inc.) was used. The forehead was used as
ground. The primary reference was Cz. In addition to EEG and
EOG, the response forces of both hands were measured, as
outlined above. EEG, EOG and force data were sampled at
500 Hz (Acquire, Neuroscan Inc.) and stored continuously on a
PC hard-disk together with stimulus and response markers. The
data were analyzed off-line using Vision Analyzer (Brain Products,
Munich). The EEG was filtered off-line with a filter band-width of
0.5-16 Hz. EEG segments beginning 200 ms before and ending
400 ms after the response were cut out and averaged separately for
correct and error responses. The ERP data were re-referenced to
average reference to make them independent on any specific
reference such as the mastoid. Only the data of the incongruent
trials were used for ERP analysis. The Ne in the error trials, and
the Nc in the correct trials, were measured as the largest negative
peak at FCz within a window of 20 to 120 ms after the response,
relative to the baseline.
Ethics
Parkinson’s disease patients were recruited from local clinics, the
neurological department of the University of Bochum and the
municipal hospital Dortmund. Healthy controls were recruited by
newspaper announcements. All participants gave written informed
consent. For the Parkinson’s disease individuals, a family member
was aware of the recruitment for the study and was involved in the
consent procedure. The study was approved by the ethics
committee of the University of Mu ¨nster.
Statistical methods
Data from fourteen de novo PD patients (N=14) and fourteen
healthy controls (N=14) were analyzed. There were no drop-outs.
Reaction times (RTs) and error rates were analyzed as behavioural
measures. Neurophysiological processes on correct and erroneous
trials were analyzed in a repeated-measures ANOVA using the
within-subject factor ‘‘correctness’’ (correct vs. error) and the
between-subject factor group (controls, de novo PD). The degrees
of freedom were adjusted using the Greenhouse-Geisser-Correc-
tion when appropriate. Significances are given one-tailed, due to
higher test-power. The mean and standard error of the mean (6
SEM) are given. Post-hoc tests were calculated using the
Bonferroni-correction. Due to higher test power, one-sided tests
were performed. For statistical analysis SPSS 15.0 was used.
Results
Behavioral data
Reaction times (RTs) on error and correct trials were subjected
to a repeated measures ANOVA with the within-subject factor
‘‘correctness’’ and the between-subject factor ‘‘group’’. RTs
differed between error and correct trials, being significantly longer
on correct (512.1613.4) than on error trials (345.07612.1)
(F(1,26)=342.78; p,.001). Additionally, there was a main effect
‘‘group’’ (F(1,26)=6.01; p=.021), showing RTs to be longer in the
de novo group (457.9616.9) than in the control group
(399.2616.9). There was no interaction ‘‘correctness6group’’
(F(1,26)=0.2; p..8), indicating that RTs were always longer for
correct than for error trials, regardless of group.
For the error rates also a repeated measures ANOVA was
calculated using the within-subject factor ‘‘trial type’’ (congruent,
incongruent, Nogo) and the between-subject factor ‘‘group’’. A
significant main effect of trial type was obtained (F(2,52)=50.96;
p,.001; g=.66), where it is shown that error rates were lowest on
congruent trials (0.5260.13), followed by Nogo-trials (3.6160.61)
and incongruent trials (13.4761.75). All trial types differed from
each other (p,.001). For the error rates, there was no main effect
of group (F(1,26)=0.02; p..8) and no interaction ‘‘trial type6
group’’ (F(2,52)=0.16; p..8). No main effect of slowing was seen
(F(1,26)=1.34; p..2), which was the case for both groups, as the
non-significant interaction reveals (F(1,26)=.09; p..7).
Neurophysiological data
Figure S2 shows the response-locked ERPs after correct and
incorrect responses for de novo patients and controls at FCz.
A clear Ne is seen for error trials, while the correct trials exhibit
a smaller negativity with shorter latency, the Nc. The Ne appears
smaller, and the Nc larger in the patients vs. the controls. The
difference between Ne and Nc appears very small in the patients.
Neurophysiological data were analyzed in a repeated measures
ANOVA using the within-subject factor ‘‘correctness’’ and the
between-subject factor ‘‘group’’. The amplitudes of ERPs after
error and correct responses differed from each other
(F(1,26)=23.63; p,.001), with the Ne being more negative
(25.7960.58) than the Nc (22.1760.43). While there was no
main effect ‘‘group’’ (F(1,26)=.044; p..5), there was significant
interaction ‘‘correctness6group’’ (F(1,26)=10.89; p=.003). Bon-
ferroni-corrected post-hoc tests revealed that the groups differed
on error trials (F(1,26)=6.28; p=.019), with the Ne being larger in
the control group (27.2560.82), than in the de novo group
(24.3360.82). For the Nc the pattern was reversed, as the Nc was
larger in the de novo group (23.1660.61), compared to controls
(21.1960.61) (F(1,26)=5.23; p=.031). For the de novo PDs it is
shown that the Ne differed from the Nc (F(1,13)=5.43; p=.037;
g=.29). Yet, in the control group this difference was larger
(F(1,13)=34.92; p,.001; g=.73). Values for the Ne and Nc for
each individual patient-control pair are given in Figure S3.
The amplitude of the Ne in the de novo group was unrelated to
their RTs in error trials, even though they were prolonged,
compared to controls (r,.1; p..4). For the correct only a trend
towards a relation was obtained (r=2.404; p=.066). Correlating
the Ne and Nc amplitudes with the BDI score, only revealed
significant correlations in the de novo PD group, but not in the
controls (Ne: r=2.627; p=.008; Nc: r=2.501; p=.034). The
correlation shows that a higher BDI score was related to higher Ne
or Nc amplitudes. Yet, in no de novo PD patient the BDI was
above the critical cut-off value.
Regarding the latencies, a similar repeated measures ANOVA
revealed a main effect ‘‘correctness’’ (F(1,26)=11.97; p=.002),
with the latency of the Ne (74.6467.62) being longer than the
latency of the Nc (43.2165.09). While the interaction ‘‘correct-
ness6group’’ was significant (F(1,26)=4.24; p=.049), post-hoc
test did not reveal effects (all F’s,2.9 p..1). There was also no
main effect ‘‘group’’ (F(1,26)=1.52; p..2).
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residual stimulus-related ERPs. To rule out this possibility, we
computed stimulus-locked waveforms on correct trials. As can be
seen in Figure S4 amplitudes were not higher in the PD, compared
to the control group (F(1,26)=2.22; p..15). Hence, even if the Nc
is affected by these stimulus-locked ERPs it should have been
modulated in the opposite direction, i.e. there should be a
reduction of the Nc in de novo-PDs, which was not the case. Thus,
the ERP waveforms obtained for the Nc are unlikely to be biased
due to differences in stimulus processing.
Discussion
In the current study we assessed post-response processing
functions in recently diagnosed PD-patients, compared to healthy
controls. While the Ne was reduced even in the de novo patients,
relative to healthy controls the Nc was enhanced in the patients.
This pattern cannot be attributed to different performance levels,
as the groups did not differ in error rates.
Furthermore, it can be ruled out that the Nc waveform is
contaminated by residual stimulus-related ERPs, since the
stimulus-locked ERP amplitudes in correct trials were not higher
in the PD, compared to the control group. However, the RTs were
generally prolonged in the de novo PD-group, which is likely due
to the pathogenic mechanisms. In an earlier study [10] the (well-
medicated) patients had no prolonged RTs in comparison to
matched controls in the same flanker task. This suggests that L-
DOPA medication speeds up RT [37]. The prolongation of RTs
seems to be unimportant for the modulation of the Ne, as no
correlation was found between these parameters. As basic
neuropsychological scores did not differ between the groups the
results show a clear advantage of neurophysiological measures
compared to standard neuropsychological test for detecting early
cognitive changes in PD.
The reduction of the Ne in the patient group is in line with the
reinforcement-learning hypothesis [3]. In light of this, it is
interesting that phasic DA signals in medial frontal areas, as they
are reflected in the Ne, are decreased, while neurophysiological
processes as they are reflected by the Nc, are enhanced. As
hypothesized in the introduction, Nc and Ne may both depend
on the activity of the DA-system serving as a gating signal that
instructs the network when to maintain a given activity state [4].
This may strengthen current representations, protecting them
against interference by irrelevant distracting information [4,5].
Given this, the results suggest that de novo PD-patients show an
increased overall motor response monitoring (Nc) [13] and hence
a strengthening of motor response representations. It may be
hypothesized that this alteration in medial frontal activity is at
costs of error-specific dopaminergic increases: the system
controlling motor response monitoring is more demanded in
de novo patients, than in controls. If this system is controlled by
the DA-system dopaminergic prefrontal neuron assemblies may
not be able to alter their firing in order to be capable of the
demands that error monitoring processes add on these [13]. In
healthy subjects, where dopaminergic neuron assemblies are less
strained during motor response monitoring this alteration in
firing is possible to a larger extent. Together, these processes
may result in a pattern of an increased Nc and a reduced Ne. In
our previous studies [8,10] the Nc was not found to be
significantly altered in long-term medicated patients. This
pattern of results in de novo PD-patients may be an expression
of compensatory processes, which are likely mediated via
dopaminergic neurons in PD [38]. However, other studies have
not proved the importance of this system [28]. Even though
these are predominantly manifest in presymptomatic stages of
PD [38] they may persist with reduced efficacy in very early
stages of PD (i.e. de novo PD). This pattern of reduced Ne and
enhanced Nc resembles what is often seen in healthy elderly vs.
young subjects, or in frontal brain patients vs. elderly subjects
[18]. Hence a pattern of compensatory enhancement of small
DA signals at the cost of strong DA signals after errors appears to
exist in normal aging and some CNS diseases. Critical for this
interpretation in terms of a general mechanism, may be the
finding that the scalp topographies of the Nc and Ne were only
similar in the de novo PD group, but not for the controls.
Hence, and more probable the results in the PD-group, may be
due to an impairment of the correct response representation that
may be due to prefrontal dysfunctions in PD [23–25]. Therefore
errors are not always detected and correct responses may
sometimes be misinterpreted as errors. Such an alternative
interpretation has been put forward by Coles et al. [22]. This is
also supported by the current data, since the topographies were
similar for correct and error trials, but only for the de novo PD
group and not for controls. As RTs were prolonged in the de novo
group, likely due to a general slowing of motor functions, it may
also be hypothesized that this slowing in RTs is an expression of
such an increased, overall response monitoring in an early stage of
PD. It is possible that the higher BDI score in the de novo patients
led to altered response monitoring (Nc) although the Ne amplitude
is significantly reduced in the de novo patients, compared to
controls.
From a clinical point of view it is highly relevant that the Ne
reduction is fairly large in just diagnosed patients which exhibit
only subtle signs of manifest PD (UPDRS part III of 12.7). Hence
the Ne may have the potential for an additional diagnostic tool in
the early diagnosis of PD. Future clinical studies have to show,
whether observed modulations of the Ne are specific for various
neurodegenerative diseases (e.g. PD, Huntington’s disease, supra-
nuclear palsy) as well as other neurological diseases (e.g. multiple
sclerosis) and stages within a disease.
Future longitudinal studies may further examine, if the Ne
becomes larger and the Nc reduced due to treatment in the course
of the disease, suggesting that Ne and Nc may also be useful
markers of treatment success.
Supporting Information
Figure S1 Stimulus arrays of the modified flanker task. Depicted
are the stimuli for congruent, incongruent (right hand responses)
and for Nogo (no response) condition.
Found at: doi:10.1371/journal.pone.0004898.s001 (0.22 MB TIF)
Figure S2 Event-related potentials of the Ne and Nc. The error
trials (continuous lines) and correct trials (dashed lines) for de novo
PD (dn) (red lines) and controls (green lines) at electrode FCz. R
denotes the time of the response. Topographies for error and
correct trials separated for the groups are given below.
Found at: doi:10.1371/journal.pone.0004898.s002 (0.20 MB
TIF)
Figure S3 Scatter plots for the Ne amplitude (upper plot) and Nc
amplitude (lower plot) for each individual patient-control pair.
Found at: doi:10.1371/journal.pone.0004898.s003 (0.13 MB
TIF)
Figure S4 Stimulus-locked ERPs on correct trials for PD
patients and controls. Time point ‘‘S’’ denotes the stimulus
onset.
Found at: doi:10.1371/journal.pone.0004898.s004 (0.87 MB TIF)
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